Extramedullary (EM) plasmacytomas (EMPs) that are not progression of intramedullary (IM) plasma cell myeloma (PCM) are usually indolent. In contrast, EM spread of IM PCM is associated with a poor prognosis. The recently introduced Durie-Salmon PLUS staging system includes EM disease in the poor prognosis category. One study noted an increase in EM disease both at diagnosis and during follow-up of PCM in 2000 --2007 compared with previous years raising concerns that adoption of novel agents (thalidomide, lenalidomide and bortezomib) and greater use of hematopoietic cell transplantation (HCT) might be contributory to this. It is uncertain if this is a true increase or merely greater detection due to the increasing use of more sensitive imaging techniques (computerized tomography, magnetic resonance imaging and 18 F-fluorodeoxyglucose positron emission tomography) or a reflection of the evolving natural history of PCM in an era when patients are living longer (median overall survival before 1996 was 29.9 months vs 44.8 months after 1996). Recent studies suggest there are important biological differences between PCM with or without EM spread that are offering clues that might explain the propensity for dissemination and a more aggressive clinical course. For example, EM relapse in PCM with and without deletion 13 was 30.8 vs 5.6%, suggesting the biology of a plasma cell subclone before HCT can affect the nature of the relapse after HCT. This article will explore the clinical, biological and treatment implications of EM spread of PCM. In addition, the impact of extramedullary disease on the outcomes of autologous and allogeneic HCT for PCM will be analyzed. Allogeneic HCT early in the course of high-risk PCM with EM disease is a consideration since graft vs myeloma effects may be essential to achieve maximal survival benefits.
INTRODUCTION
Plasma cell myeloma (PCM) is a clonal plasma cell malignancy, and its cells usually reside in the intramedullary (IM) spaces of the BM but when there is extension through the bone cortex or hematogenous spread to other organs, extramedullary disease (EM PCM) results. Recently, a study of 1003 PCM patients found an increase in EM spread in 2000 --2007 compared with previous years raising concerns about a correlation with the use of novel agents (thalidomide, lenalidomide and bortezomib) and/or greater use of hematopoietic cell transplantation (HCT). 1 However, the observation that the increase in EM PCM was evident both at diagnosis before treatment and after therapy suggests other factors are contributory. An increase may in part be due to the evolving natural history of PCM in its later phases in an era when patients are living longer (median overall survival (OS) before 1996 was 29.9 months vs 44.8 months after 1996). 2 The increasing use of more sensitive modern cross-sectional imaging with computerized tomography (CT), magnetic resonance imaging (MRI) and 18 F-fluorodeoxyglucose positron emission tomography (FDG PET) is clearly responsible for a considerable part of the increase, making it difficult to know whether there is a true increase in EM PCM in recent times or merely better detection. This is compounded by the variable definitions of EM PCM with some studies including only soft tissue plasmacytomas from hematogenous spread to organs while others also including extension through the bone cortex as well as plasma cell leukemia (PCL). EM spread of PCM (EM PCM) in this article will be defined as plasma cell tumor extending from the IM spaces of the BM through the cortical bone as well as spread to organs; however, hematogenous dissemination into blood vessels resulting in PCL will not be included. The IM cavity of the BM is located in the central cavity of the bone surrounded by cortical bone and these two compartments are separate functionally.
Primary EM plasmacytomas (EMPs) not accompanied by PCM or a manifestation of progression of IM PCM are usually indolent. EM spread of IM PCM is associated with a poor prognosis. 3, 4 This is similar to acute leukemia with EM disease denoting a worse prognosis. The Durie-Salmon PLUS staging system (Table 1) , recently introduced by the International Myeloma Foundation, uses whole body CT/PET or MRI spine and pelvis imaging integrated with the original Durie-Salmon staging system to define poor risk PCM patients as those with 420 bone lesions and/or EM disease (stage IIIB associated with a 19-month median OS compared with a median survival of 40 months for stage IIIA without EM disease). 3, 4 This article will explore the clinical, biological and treatment implications of EM spread of PCM. In addition, the impact of EM PCM on the outcomes of autologous and allogeneic HCT will be analyzed.
CLINICAL IMPLICATIONS Incidence
Three percent of plasma cell malignancies are in the form of primary EMP defined as a plasma cell tumor arising outside the BM with normal BM and these rarely (0.4 --15%) progress to PCM. 5 --7 The incidence of EM disease occurring at diagnosis (1.9 --19%) of PCM and during follow-up (2.3 --16%) of PCM is variable in the published literature depending on the definition of EM disease, population under study and the variable use of modern cross-sectional imaging techniques (see Table 2 ).
1,8 --12
The true incidence of EM PCM is undefined (iceberg phenomenon) making it difficult to conduct prospective trials to determine the full impact of EM disease on outcomes of PCM. However, recently in 2009, the IMWG (International Myeloma Working Group) recommended use of whole body MRI at diagnosis of PCM to give complementary information to the skeletal survey especially when the skeletal survey is negative. 13 CT is recommended by the IMWG to characterize the extent of EM PCM and guide tissue biopsy. 13 The Durie-Salmon PLUS staging system gives equivalent weight to FDG PET/CT and MRI spine and pelvis and by combining these two imaging modalities, 92% of active PCM at IM and EM sites can be detected. 3, 13 Advantages of FDG PET/CT are that it can give functional and morphologic assessments of active PCM in areas not assessed by MRI and is useful in identifying EM PCM and assessing therapeutic response in EM sites. 4 FDG PET/CT at diagnosis and during follow-up of PCM should be performed when EM spread is suspected as outlined in Table 3 .
Sites of EM disease Isolated primary EMP without PCM occurs more commonly in the nasopharynx, larynx and upper respiratory tract whereas EM PCM resulting from hematogenous spread of PCM occurs mainly in gastrointestinal tract, pleura, testis, skin, peritoneum, liver, endocrine glands and lymph nodes. 8 Central nervous system (CNS) involvement occurs in 1% of PCM cases, usually at relapse, and is associated with plasmablastic morphology, deletion of chromosome 13 and high serum lactate dehydrogenase (LDH) level.
14 Surgical scars and bone fractures can also be sites of EM PCM. 15 In a study by Varettoni et al., 1 EM disease at diagnosis of PCM infiltrated the soft tissue surrounding the axial skeleton in 85% of cases and as hematogenous spread in 15%. EM disease at diagnosis of PCM is more frequent in males, IgD PCM, lambda light chain PCM, non-secretory PCM, and patients younger than 40 years of age without prior MGUS and with extensive bony disease.
1,9,10 EM spread occurring during the course of PCM was seen in those with lower hemoglobin, lower M protein and higher LDH. 1 In a report of three PCM patients with prior exposure to the novel agents, EM relapse was associated with a shift from intact Ig to free light chain secretion (light chain escape from plateau phase), suggesting a compromise of production of intact heavy chains during clonal evolution. 16 These patients had multiple EM disease sites, plasmablastic features, renal failure, high LDH and b2 microglobulin.
EM relapse of PCM In the Spanish registry, the largest retrospective analysis of relapse patterns after autologous HCT for PCM, 14% of relapses were EM (defined as plasmacytomas in organs) detected by CT or MRI and were not associated with M protein in serum or urine or BM infiltration. 17 Concerns regarding an association of the risk of developing EM disease and the use of novel agents and autologous HCT were raised. However, in a study of 1003 plasma cell myeloma (PCM) patients followed over three time periods 1971 --1993 (at a time of conventional chemotherapy), 1994 --1999 (with the advent of autologous HCT) and 2000 --2007 (with the use of novel agents and increasing use of CT and MRI), there was a significant increase in incidence of EM disease both at diagnosis and during follow-up of PCM in 2000 --2007 (Table 2) . 1 The risk of EM relapse was not significantly increased after use of autologous HCT, bortezomib, thalidomide or lenalidomide. 1 The presence of EM disease at diagnosis of PCM was the only significant risk factor for EM recurrence, suggesting that there are differences in the innate EM disease biology to explain this rather than therapy given. The time from diagnosis of PCM to EM relapse was 18. Impact of extramedullary multiple myeloma on outcomes B Wirk et al corresponding median OS was 32 months vs 54 months (P ¼ 0.001) raising the possibility that EM relapse was part of the natural history of PCM due to longer survival.
Concerns of EM relapse risk in PCM patients undergoing reduced intensity conditioned allogeneic HCT were raised after 37% of the relapses were EM in a single center study. 18 Results on the efficacy of therapy of these EM relapses were not given in this study. 18 However, 30% of these patients had progressive disease (PD) and 10% stable disease at the time of HCT and only 21% were planned sequential autologous-allogeneic HCT with the remainder performed as salvage allogeneic HCT. 18 Furthermore in a study of myeloablative allogeneic HCT for PCM, 32% had EM relapses. 19 In all, 80% of these patients had stable disease or PD, suggesting that the status of disease at HCT rather than the conditioning increased the EM relapse risk. 19 This shows allogeneic HCT in high-risk PCM patients with PD may increase risk of EM relapse. 18, 19 Nonetheless, this is higher than the 14% of relapses as EM myeloma in the Spanish autologous HCT registry study. 17 The immunosuppressive therapy after allogeneic HCT and possibly the more effective graft vs myeloma (GVM) effect in BM vs EM sites has been implicated. 18 However, in a multicenter study of PCM patients undergoing sequential autologous-non-myeloablative allogeneic HCT where there was a 20.4% incidence of EM relapse, no association with acute or chronic GVHD, chimerism, use of antithymocyte globulin, matched or mismatched HCT and EM relapse was found. 20 None of these patients had PD at the time of HCT. DLIs were also effective in treating EM relapse. 20 Although these patients had concomitant therapy with thalidomide or bortezomib, other studies reported DLI given alone was associated with response at the EM sites. 19, 20 The only association with EM relapse was deletion of chromosome 13, an established poor prognostic factor, at diagnosis of PCM (incidence of EM relapse with and without deletion 13 was 30.8 and 5.6%, respectively). 20 This suggests that the biology of a plasma cell subclone before HCT can affect the nature of the relapse after HCT.
Similarly, Fassas et al. 14 described nine PCM patients with CNS relapse after chemotherapy at a median of 11 months from diagnosis and another nine patients with CNS relapse after autologous HCT at a median of 16.5 months from PCM diagnosis. This goes against the argument that longer survival after autologous HCT increases risk of CNS relapse since the interval from PCM to CNS relapse was not significantly different in either group. Fassas et al.
14 also found an association of deletion of chromosome 13 with CNS relapse in PCM.
Taken together, these studies suggest that biological features of a plasma cell subclone present at diagnosis are responsible for the spread into EM sites rather than the therapy given. 1,14,18 --20 BIOLOGICAL IMPLICATIONS EM spread of PCM and its poor prognosis are not clearly linked solely with advanced disease stage and seem less likely to be linked to the type of prior therapy but rather more likely associated with biologic changes in the myeloma clone. 21 Studies suggest important roles for oncogenes, cell proliferation molecules, chromothripsis, cell adhesion molecules and the microenvironment. Table 4 ). 21 p53, a tumor suppressor gene, is a nuclear phosphoprotein that regulates the cell cycle. Inactivation of p53 in PCM is associated with more aggressive disease, chemotherapy resistance and worse OS. 21 --23 Aberrant nuclear p53 protein expression can be detected by immunohistochemistry and reflects hemizygous p53 deletion. 22 CD56, a neural cell adhesion molecule, is a membrane glycoprotein expressed in 80% of PCM without EM disease but not on normal plasma cells or PCL. MIB-1 is a monoclonal antibody against Ki67, a cell proliferation-associated antigen. MIB-1 staining index of IM PCM was negligible. 21 CD56 immunoreactivity was detected in 2 of 12 IM vs 4 of 12 EM PCM samples. There was no significant difference in CD56 expression between primary isolated EMP and EM PCM or between primary EMP and IM PCM samples. 21 MIB-1 staining index was significantly greater in EM PCM samples compared with primary isolated EMP. Significantly, less p53 immunoreactivity was found in primary EMP than in EM PCM but there was no difference in p53 expression between primary EMP and IM PCM. 21 PCM patients with EM extension from bone presenting as soft tissue masses had greater p53 immunoreactivity than in paired IM samples, indicating that EM extension through the cortical bone is not just due to a greater mass of typical PCM but is a different biologic entity. Nuclear p53 immunoreactivity and increased cell proliferation but not CD56 expression were associated with EM spread of PCM. 21 Targeted therapies to restore p53 function in providing genomic stability may be a potential clinical application to treat EM spread of PCM.
The cell-cycle protein cyclin D1 (CCND1) as a result of t(11;14) (q13;q32) is expressed in a third of PCM patients and is absent in primary EMP. 24 Detection of CCND1 in EM plasma cell infiltrates is suggestive of underlying PCM. Kremer et al. 24 analyzed non-paired samples from IM PCM, EM PCM (occurring as plasmacytomas in the pharynx, nasal cavity, orbit, spleen or muscle) and primary EMP for CCND1. EM PCM was associated with high-grade plamsablastic morphology in comparison with the well-differentiated plasma cells seen in IM PCM and primary EMP. CCND1 overexpression and CD56 expression were seen in EM PCM and IM PCM but not in primary EMP and this highlights that PCM and primary EMP are distinct entities rather than different manifestations of the same disease. 24 RAS pathway activation by cytokines such as IL-6 promotes growth of PCM and can also suppress apoptosis. 25 In a study of EM PCM, paired IM and EM PCM had the same IgH gene rearrangements with germline RAS in the IM PCM samples and mutated RAS in the EM PCM samples only. 25 This suggests that EM spread of PCM may be facilitated by RAS mutations. Chromothripsis Cancer, including PCM, is traditionally thought to result from a progressive accumulation of gene rearrangements and mutations over time. Chromothripsis, Greek for chromosome shattering into pieces, occurs in a single catastrophic event resulting from chromosome breakage when the chromosome is condensed for mitosis. 26 This occurs at diagnosis of 2 --3% of primary tumors and can result in hundreds of gene rearrangements. The etiology is unknown but possibly related to breakage-fusion-bridge cycle due to telomere wear and tear. 26 The majority of the affected cells die but some survive after undergoing repair of the chromosome into a derivative chromosome, which could result in loss of tumor suppressor genes or amplification of oncogenes promoting malignancy. 26 Karyotypic abnormalities accumulate according to the stage of PCM (20% in stage I, 60% in stage III and 480% in EM PCM). 27 Translocations involving 14q32 are seen in 20 --40% of PCM and are higher in EM PCM, usually with CCND1 11q13. 27 For example, there was an association of CNS spread of PCM with plasmablastic morphology and deletion of chromosome 13 in paired BM and cerebrospinal fluid samples.
14 There is evidence for evolution of PCM in a multistep transformation process over time from MGUS to IM PCM and in a fraction of patients to EM PCM. 27 However, in a study of 764 newly diagnosed PCM patients, single-nucleotide polymorphism arrays identified complex genomic rearrangements suggestive of chromothripsis in 1.3% (10 patients) and these patients had a median survival of 12 months only. 28 For example, a 34-year-old patient with PCL at diagnosis with chromothripsis died in 6 months. 28 Chromosomes 1q and 16q in particular were affected by copy number rearrangements in PCM patients. 28 Chromothripsis occurs at diagnosis and results in poor prognosis PCM. 28 The median survival of 12 months in these PCM patients with chromothripsis at diagnosis suggests that this is a different biologic entity from PCM patients surviving 410 years. 28 Cell adhesion molecules Other studies on plasma cells from malignant effusions indicate loss of CD56 is associated with EM spread but this may not be true for EM PCM in solid organ sites. 24, 29, 30 In a study of six secondary PCL patients with paired BM and peripheral blood samples, CD56 was absent from both sites, indicating loss of CD56 occurred in the BM and was associated with dissemination. 29 Mechanisms that control CD56 expression are not well understood. In a study of seven PCM patients with paired samples from EM sites of involvement (mainly ascites and pleural effusions), there was downregulation of CD56 in the EM sites. 30 The BM showed different subsets with respect to CD56 expression but always one subset corresponding to the EM PCM cells.
30 CD44, a cell adhesion molecule, was expressed more in EM sites than in IM PCM. Heavy chain immunoglobulin (IgH) gene rearrangements were the same in EM and IM sites from each patient, signifying a population of clonal malignant plasma cells with different homing characteristics. The mechanism of EM spread of PCM (to ascitic fluid, pleura or solid tumors) differs from PCL as highlighted by the observation that there are usually few circulating plasma cells with EM PCM. 
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In humans, stromal-derived factor-1 alpha/CXCR4 axis is primarily involved in myeloma cell homing to the BM. 31 BM endothelial cells secrete stromal-derived factor-1 alpha, which is a ligand of the chemokine receptor CXCR4 allowing adhesion of myeloma cells to the BM stroma. Myeloma cells express adhesion molecules such as VLA (very late activation antigen)-4, CD56 and CD44, which also allow interaction with receptors, such as vascular cell adhesion molecule-1, on the BM endothelium. 31 Decreased expression of these adhesion molecules could contribute to EM spread. For example, thalidomide exposure resulted in decreased VLA-4, CD56 and CXCR4 expression in myeloma cells. 32 Similarly, bortezomib was associated with decreased VLA-4 and CXCR4 expression. 33 
Microenvironment
Rabbit bones implanted subcutaneously in unconditioned SCID mice (SCID-rab model) allowed growth of human myeloma with comparable growth patterns as that seen in humans. 34 This was mostly IM human myeloma in the rabbit BM microenvironment; however, cells from EM PCM patients resulted in growth of human EM PCM along the outer surface of the rabbit bones with endothelial cells and stromal cells of the rabbit also found in the EM sites. 34 The rabbit microenvironment cells were still needed for growth at EM sites.
In a study of six EMP patients, three of whom also had BM involvement with o13% plasma cells, an angiogenesis-associated gene expression profile (angiopoietin 1, Notch 3 and fibronectin 1) was found. 35 Immunohistochemical staining showed CD31 and endoglin protein expression in these EM lesions, which could allow growth outside the BM. 35 Clearly, further study is needed to fully understand the biology of EM spread and to identify the genes required to induce blood vessel formation and stromal cell support needed for EM spread of PCM.
In summary, these studies suggest that there is a malignant phenotype favoring EM spread of PCM, including high plasma cell proliferation (MIB-1 overexpression), alterations in adhesion molecules (downregulation of CD56 and overexpression of CD44), angiogenesis gene expression profile (overexpression of angiopoietin 1, notch 3, fibronectin 1, CD31 and endoglin protein), deletion of p53 and chromosome 13, CCND1 overexpression and RAS mutations. 21, 24, 25, 30, 31, 35 TREATMENT IMPLICATIONS Despite recognition of its impact on prognosis, the impact of EM PCM on treatment outcomes has not been fully studied. There is a paucity of prospective data from both chemotherapy and HCT randomized trials. Radiation therapy is the standard therapy for solitary bone plasmacytomas and solitary EMPs. 5 Radiation therapy is less defined for EM PCM where the emphasis is on systemic therapy with chemotherapy and/or HCT. Radiation therapy is used in conjunction with systemic therapy in EM PCM where there is local compromise such as cord compression for example.
Chemotherapy
Many large phase III prospective chemotherapy trials in PCM were not designed to analyze results for PCM with or without EM spread separately. Efficacy of chemotherapy in newly diagnosed PCM with EM spread is poorly studied and based mostly on case reports and small retrospective studies of patients with relapsed or refractory PCM. For example in a study of 11 patients with relapsed/refractory EM PCM given the antiangiogenic agent thalidomide, despite a BM and serologic response, there was progression at EM sites possibly due to differences in the microvasculature of the BM vs EM sites. 36 However, other case reports found thalidomide combined with dexamethasone or alkylating agents to be effective in both IM and EM PCM. 37, 38 Biagi and Prince 39 reported three PCM patients with EM relapse after allogeneic HCT responded to thalidomide. The response to thalidomide was postulated to be more due to the augmentation of GVM effects than antitumor effects. 39, 40 Similarly, a patient with relapsed/refractory EM PCM post-allogeneic HCT attained CR with bortezomib also by enhancing GVM effects. 41 In a randomized phase III trial, the Spanish Myeloma Group assessed induction chemotherapy before autologous HCT in newly diagnosed PCM patients, 18% of whom had EM PCM at diagnosis. 42 Bortezomib, thalidomide and dexamethasone (VTD) resulted in higher CR pre-and post-autologous HCT. The progression rate was higher in the thalidomide, dexamethasone (TD) arm than in the VTD arm (21 vs 8%). PD was also higher in the PCM patients with EM spread (34 vs 12%) ; however, in this high-risk group the PD rate was still lower with VTD. 42 The estimated 2-year OS was 82% and the same in each treatment arm. Separate results regarding OS in patients with or without EM disease were not reported in the abstract.
A 31% response rate, including 2 patients with CR, with the new immunomodulatory drug, pomalidomide was achieved in 16 relapsed/refractory PCM patients with EM disease, 3 of whom had EM disease since diagnosis of PCM with the remainder described as treatment emergent EM disease. 12 The median OS was 16 months in those with EM disease vs not yet reached for those without EM disease. 12 Responses to lenalidomide were also seen in 27 relapsed/refractory PCM patients with EM spread with 46% CR in the EM sites with an overall response rate of 77%. 43 The Intergroupe Francophone du Myelome is conducting a prospective phase III MM020 (NCT00689936) trial where patients ineligible for autologous HCT with de-novo PCM are randomized to receive 12 cycles of melphalan, prednisone, thalidomide (MPT) vs 18 cycles of lenalidomide and low dose dexamethasone (Rd) vs Rd until progression. Follow-up of EM sites of PCM is compulsory in this trial to assess responses as outlined in the international uniform response criteria for PCM. 44, 45 More trials designed to analyze the results of therapy in PCM with or without EM disease at diagnosis or during the course of disease are needed to fully understand the impact of EM disease on prognosis.
Autologous HCT The large prospective phase III studies in HCT have not been designed to analyze the impact of EM disease on outcomes of HCT. The data available on the prognostic impact of EM disease at diagnosis in PCM are from retrospective studies but still provide important insights (see Table 5 ). In a study by Varettoni et al. 1 , time-dependent analysis of 56 patients showed that EM disease at any time in the course of PCM was associated with significantly shorter progression-free survival (PFS) and OS than PCM without EM disease. After adjusting for age and stage, the presence of EM disease still had a negative impact on PFS and OS by multivariate analysis. The negative impact of EM disease was overcome by autologous HCT but not by chemotherapy including the novel agents.
1 This is in contrast to a smaller study by Damaj et al. 8 who found EM disease at diagnosis in 10 PCM patients was associated with poorer OS than EM spread in the course of the disease in 9 patients (median survival 12 months vs 24 months, P ¼ 0.03) even in those treated with autologous HCT.
Wu et al. 11 analyzed the results of 75 patients with EM disease at diagnosis of PCM compared with those without EM spread and found that despite a similar response to chemotherapy (cyclophosphamide, thalidomide and dexamethasone), there was a significantly shorter OS for PCM with EM disease than those without EM spread. However, autologous HCT was able to provide a significantly improved OS in both groups but the greatest impact was felt in those with EM PCM at diagnosis with similar trends seen in PFS. 11 When adjusted by independent risk factors (age, calcium, b2 microglobulin, albumin, thalidomide and autologous HCT exposure), there was no difference in OS in PCM patients with or without EM spread at diagnosis who received autologous HCT inferring autologous HCT can overcome the negative impact of EM disease. 11 Autologous HCT was able to achieve responses in EM sites even in patients who had no response to chemotherapy at EM sites despite a serologic response.
11
Allogeneic HCT A case report of a patient with EM PCM relapse after allogeneic HCT responding to DLI in the IM sites but not in the EM sites raised questions about the efficacy of GVM effects at the EM sites. 46 However, Minnema et al. 20 in a multicenter study of 172 patients undergoing sequential autologous-allogeneic HCT found DLI to be equally effective in EM relapse and IM relapse (see Table 6 ). There was no difference in OS or PFS in those with or without EM at relapse or in those with EM relapse alone or as part of systemic relapse. 20 Shorter survival was seen in those with high b2 microglobulin at diagnosis or relapse before autologous HCT. Longer OS was found in those with response to allogeneic HCT, with chronic GVHD and low LDH at diagnosis. 20 Shorter PFS was associated with relapse before autologous HCT and o95% donor chimerism at 3 months after allogeneic HCT. The response to therapy and the OS/PFS were similar in those with PCM relapse with or without EM disease, challenging the association of therapy resistance and poor prognosis with EM relapse after allogeneic HCT. 20 Zeiser et al. 19 also found the same PFS and OS in patients relapsing after autologous or allogeneic HCT in EM or IM sites (see Table 6 ); however, more patients relapsing with EM than IM disease after autologous HCT underwent allogeneic HCT (67 vs 40%) which could have biased these results but do suggest the utility of allogeneic HCT for PCM with EM relapse. Patients with EM or IM relapse after allogeneic HCT had similar acute or chronic GVHD rates, suggesting that both groups were equally immunosuppressed and contradicting the idea that EM relapse arises in immunologically privileged sanctuary sites escaping the GVM effect. Furthermore, the response to DLI was similar in both groups of EM or IM relapse after allogeneic HCT. In the Minnema et al. 20 report, some of the patients had received combination chemotherapy with bortezomib or thalidomide and DLI raising the possibility of antitumor effects of the chemotherapy accounting for the regression of the EM disease. However, thalidomide and bortezomib may have also potentiated the GVM effect at the EM sites. 40, 47 Furthermore in the report by Zeiser et al. 19 PCM patients with EM relapse received DLI alone and achieved responses similar to those with IM relapse signifying the impact of GVM effects at EM sites. For example, a PCM patient with multiple subcutaneous plasmacytomas after allogeneic HCT responded to DLI with durable CR. 19 Terpos et al. 48 described isolated EM relapse after autologous or allogeneic HCT to herald systemic relapse by a median of 6 months. The prognosis of EM relapse was poor with 73% dying after receiving combinations of chemotherapy, radiation therapy, second autologous or allogeneic HCT for a median survival of 12 months (range 1 week to 28 months). The variable outcomes may be due to diverse plasma cell subclones or the therapy received. The PCM patient with EM relapse surviving the longest (28 months) had a second mini-allogeneic HCT followed by DLI which highlights the benefits of the GVM effect. 48 Fassas et al.
14 described 18 patients with CNS relapse, 9 after autologous HCT and 9 after chemotherapy (Total Therapy I). Seventeen patients died at a median of 5 months (range 4 days to 25 months) after diagnosis of CNS MM. One patient remained alive at 12 months from diagnosis of CNS relapse after prior autologous HCT and 33 months from MM diagnosis. This patient received an allogeneic HCT after the diagnosis of CNS relapse and remained free from CNS or systemic PCM. Another long-term survivor was also treated with an allogeneic HCT and died of chronic GVHD at 25 months after CNS relapse while remaining free from systemic or CNS PCM.
14 Thus, the only two long-term survivors in this high-risk group of CNS PCM had allogeneic HCT which is suggestive of GVM effects. The recommendations from this study were that high-risk PCM patients with deletion of chromosome 13, plasmablastic morphology, high LDH with EM disease such as CNS PCM should have allogeneic HCT as consolidation early in the course of the disease to achieve maximal survival benefits. 14 In summary, these studies suggest that the negative impact of EM disease at diagnosis of PCM can be overcome by autologous Impact of extramedullary multiple myeloma on outcomes B Wirk et al HCT but not by chemotherapy, including the novel agents. 1 PCM with EM relapse after autologous HCT benefits from allogeneic HCT. 19 DLI is equally effective for EM or IM PCM relapse after allogeneic HCT signifying the value of GVM effects. 19, 20, 48 High-risk PCM patients with deletion of chromosome 13, plasmablastic morphology, high LDH with EM disease such as CNS PCM should have allogeneic HCT as consolidation early in the course of the disease to achieve maximal survival benefits. 14 
CONCLUSIONS
Use of the IMWG guidelines for modern cross-sectional imaging in PCM and the IMWG uniform response criteria, which require resolution of soft tissue plasmacytomas as well as a serological response to define CR, will allow better definition of the incidence and outcomes of EM disease in PCM. 13, 45 EM spread of PCM and its poor prognosis are not clearly linked solely with advanced disease stage and seem less likely to be correlated with the type of prior therapy but rather more likely associated with biologic changes in the myeloma clone. Bortezomib, thalidomide, lenalidomide or autologous/allogeneic HCT for PCM do not increase the risk of EM relapse. 1,14,18 --20 The only significant risk factor for EM relapse after autologous HCT was EM disease at diagnosis of PCM.
1 PD at time of HCT and deletion of chromosome 13, all established poor prognostic factors, were the only significant factors associated with EM relapse after allogeneic HCT. 19, 20 This suggests that it is the biology of a plasma cell subclone before HCT that affects the nature of the relapse after HCT. PCM patients with EM or IM relapse had similar acute or chronic GVHD rates and response to DLI, contradicting the idea that EM relapse arises in immunologically privileged sanctuary sites escaping the GVM effect. 19, 20 The presence of EM disease at diagnosis of PCM has a negative impact on PFS and OS which can be overcome by autologous HCT but not by chemotherapy including the novel agents. 1, 11 Zeiser et al. 19 showed that PCM patients with EM or IM relapse after autologous or allogeneic HCT had the same PFS or OS. However, more patients with EM relapse than IM relapse after autologous HCT underwent salvage allogeneic HCT, which could have biased these results. Nonetheless, this does attest to the efficacy of allogeneic HCT and the benefits of GVM effects in PCM with EM relapse. High-risk EM PCM patients with deletion of p53 or chromosome 13, plasmablastic morphology, and high LDH should have allogeneic HCT early in the course of the disease since GVM effects may be essential to achieve long-term survival. 14, 21, 23 Future directions Angiogenesis-associated gene expression profile (angiopoietin 1, Notch 3 and fibronectin 1), deletion of p53, RAS mutations and alterations in the expression of adhesion molecules such as CD44 or CD56 could allow growth of plasma cells outside the BM. 21, 25, 30, 35 Inactivation of p53, found more commonly at EM sites of PCM, is associated with more aggressive disease, chemotherapy resistance and worse OS. 21 --23 Targeted therapies to restore p53 function may be a potential clinical application for treatment of EM PCM. 49, 50 For Impact of extramedullary multiple myeloma on outcomes B Wirk et al example, disruption of ceramide glycosylation by silencing glucosylceramide synthase can restore wild-type p53-dependent apoptosis in mutant p53 tumor cells and can provide a new strategy to eradicate these mutant p53 tumors. 49, 50 Further study to identify the genes required for blood vessel formation and stromal cell support needed for EM spread of PCM may also provide therapeutic targets. Future prospective phase III clinical studies should be designed to analyze the results of PCM with or without EM spread separately to fully define the impact of EM disease on prognosis and the optimal therapeutic strategies.
